NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Paclitaxel市場的相關調查報告書(2021年∼2025年)

Investigation Report on China's Paclitaxel Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008262
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Paclitaxel市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Paclitaxel Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

在中國市場的Paclitaxel的銷售量從2016年到2019年年年增加。從2018年的21億6,800萬人民幣到2019年增加到30億5,300萬人民幣,年度成長率最高40.86%。從2016年到2020年的中國市場中Paclitaxel的銷售額為7.16%的年複合成長率,根據2020年,由於一元化的採購急劇降價,Paclitaxel的銷售額以-18.64%的成長率減少。

中國的Paclitaxel的銷售量從2021年到2025年預計隨著乳癌患者增加而踏實增加。Paclitaxel包含在2021年的全國藥價談判中,今後銷售量也預計持續增加。

本報告提供中國的Paclitaxel市場的相關調查,市場規模和預測,趨勢,COVID-19的影響,價格,成長要素和機會,威脅,課題,市場佔有率等資訊。

目錄

第1章 Paclitaxel的相關概念

  • Paclitaxel的適應症
  • 中國的Paclitaxel的開發
  • 中國的Paclitaxel的政府核准
  • COVID-19對中國的Paclitaxel銷售的影響

第2章 中國的Paclitaxel銷售(2016-2020)

  • Paclitaxel的銷售量
    • 總銷售額
    • 各地區的銷售量
  • Paclitaxel的銷售量
    • 整體銷售量
    • 各地區銷售量
  • 中國的各劑型Paclitaxel銷售(2016-2020)
    • LIPOSOME注射
    • 注射(奈米粒子白蛋白結合)
    • 注射
    • 其他的劑型分析

第3章 中國的主要Paclitaxel製造商分析(2016-2020)

  • 主要Paclitaxel製造商市場佔有率分析
    • 各銷售額市場佔有率調查
    • 各銷售量市場佔有率調查
  • Nanjing Luye Pharmaceutical Co., Ltd.
    • 企業簡介
    • LIPOSOME(Nanjing Luye Pharmaceutical Co., Ltd.的Paclitaxel)在中國的銷售
  • CSPC Ouyi Pharmaceutical Group Co., Ltd.
    • 企業簡介
    • Keaili(CSPC Ouyi Pharmaceutical Group Co., Ltd.的Paclitaxel)在中國的銷售
  • Jiangsu Hengrui Pharmaceutical Co., Ltd.
    • 企業簡介
    • Aiyue(Jiangsu Hengrui Pharmaceutical Co., Ltd.的Paclitaxel)在中國的銷售
  • Hospira Australia Pty Ltd
    • 企業簡介
    • Paclitaxel(Hospira Australia Pty Ltd的Paclitaxel)在中國的銷售
  • Beistol-Myers Squibb Srl
    • 企業簡介
    • TAXOL(Beistol-Myers Squibb Srl's Paclitaxel)在中國的銷售

第4章 中國的各製造商Paclitaxel的價格(2020-2021)

  • Nanjing Luye Pharmaceutical Co., Ltd. (LIPOSOME)
  • CSPC Ouyi Pharmaceutical Group Co., Ltd. (Keaili)
  • Jiangsu Hengrui Pharmaceutical Co., Ltd. (Aiyue)
  • Hospira Australia Pty Ltd (ANZATAX)
  • Beistol-Myers Squibb S.r.l.(TAXOL)

第5章 中國的Paclitaxel市場預測(2021-2025)

  • 中國的Paclitaxel市場開發的有影響力的要素
    • COVID-19對中國的Paclitaxel市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105497

Paclitaxel is a chemotherapeutic tumor drug used to treat metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months after adjuvant chemotherapy. Its product, developed by Abolis, was approved by the FDA in 2005 and was approved in China in 2008. By 2020, there are 34 manufacturers in the Chinese Paclitaxel market, with Nanjing Luye Pharmaceutical Co., Ltd. accounting for the most market share in the Chinese Paclitaxel market.

According to CRI analysis, the sales of Paclitaxel in the Chinese market increased year by year from 2016 to 2019. Among them, the annual growth rate of 40.86% was the highest in 2019, from CNY2.168 billion in 2018 to CNY3.053 billion in 2019. In 2020, the hospital's overall diagnosis and treatment services were impacted by the Covid-19 epidemic, and Paclitaxel was included in the second batch of national organization drug procurement due to more than 3 manufacturers. With the sharp price reduction in centralized procurement, Paclitaxel sales have declined with a growth rate of -18.64%. The CAGR of Paclitaxel sales in the Chinese market from 2016 to 2020 was 7.16%.

CRI analyzes that the Paclitaxel sales in China will increase steadily with the increase in breast cancer patients from 2021 to 2025. In 2020, the number of new cases of breast cancer worldwide reached 2.26 million, and breast cancer is the most commonly diagnosed cancer, overtaking lung cancer. Therefore, the sales and sales volume of Paclitaxel for the treatment of breast cancer will increase accordingly with the increase in the number of patients diagnosed. Furthermore, Paclitaxel will be included in the National Drug Price Negotiation in 2021, and then its sales will keep a continuous rise. In addition, the effective alleviation of the Covid-19 epidemic will lead to a recovery growth in the sales of Paclitaxel.

Topics Covered:

  • The impact of COVID-19 on China's Paclitaxel market
  • Sales value of China's Paclitaxel 2016-2020
  • Competitive landscape of China's Paclitaxel market
  • Prices of Paclitaxel in China
  • Prices of Paclitaxel in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Paclitaxel market
  • Prospect of China's Paclitaxel market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Paclitaxel       

  • 1.1 Indications for Paclitaxel       
  • 1.2 Development of Paclitaxel in China
  • 1.3 Governmental Approval of Paclitaxel in China
  • 1.4 The Impact of COVID-19 on Paclitaxel sales in China

2 Sales of Paclitaxel in China, 2016-2020   

  • 2.1 Sales Value of Paclitaxel
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Paclitaxel     
    • 2.2.1 Overall Sales Volume  
    • 2.2.2 Sales Volume by Regions    
  • 2.3 Sales of Paclitaxel by Dosage Form in China, 2016-2020    
    • 2.3.1 Liposome injection
    • 2.3.2 Injection (nanoparticle albumin-bound)
    • 2.3.3 Injection
    • 2.3.4 Analysis of Other Dosage Forms

      

3 Analysis of Major Paclitaxel Manufacturers in China, 2016-2020   

  • 3.1 Analysis of Market Share of Major Paclitaxel Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value    
    • 3.1.2 Investigation on Market Share by Sales volume 
  • 3.2 Nanjing Luye Pharmaceutical Co., Ltd. 
    • 3.2.1 Enterprise Profile 
    • 3.2.2 Sales of LIPOSOME (Nanjing Luye Pharmaceutical Co., Ltd.'s Paclitaxel) in China

3.3  CSPC Ouyi Pharmaceutical Group Co., Ltd.

    • 3.3.1 Enterprise Profile 
    • 3.3.2 Sales of Keaili (CSPC Ouyi Pharmaceutical Group Co., Ltd.'s Paclitaxel) in China
  • 3.4 Jiangsu Hengrui Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile 
    • 3.4.2 Sales of Aiyue (Jiangsu Hengrui Pharmaceutical Co., Ltd.'s Paclitaxel) in China
  • 3.5 Hospira Australia Pty Ltd
    • 3.5.1 Enterprise Profile 
    • 3.5.2 Sales of Paclitaxel (Hospira Australia Pty Ltd's Paclitaxel) in China
  • 3.6 Beistol-Myers Squibb S.r.l.
    • 3.6.1 Enterprise Profile 
    • 3.6.2 Sales of TAXOL (Beistol-Myers Squibb S.r.l.'s Paclitaxel) in China

4 Prices of Paclitaxel for Different Manufacturers in China, 2020-2021

  • 4.1 Nanjing Luye Pharmaceutical Co., Ltd. (LIPOSOME) 
  • 4.2 CSPC Ouyi Pharmaceutical Group Co., Ltd. (Keaili)
  • 4.3 Jiangsu Hengrui Pharmaceutical Co., Ltd. (Aiyue)
  • 4.4 Hospira Australia Pty Ltd (ANZATAX)
  • 4.5 Beistol-Myers Squibb S.r.l.(TAXOL)

5 Prospect of Chinese Paclitaxel Market, 2021-2025

  • 5.1 Influential Factors of Chinese Paclitaxel Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Paclitaxel Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size 
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Paclitaxel Liposome Injection Registration in China
  • Chart Patent Information About Paclitaxel (Nanoparticle Albumin-bound) Injection Registration in China
  • Chart Patent Information About Paclitaxel Injection Registration in China
  • Chart Sales Value of Paclitaxel Liposome Injection over the World   
  • Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) over the World
  • Chart Sales Value of Paclitaxel Injection over the World
  • Chart Sales Value of Paclitaxel Liposome Injection in China, 2016-2020  
  • Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) in China, 2016-2020
  • Chart Sales Value of Paclitaxel Injection in China, 2016-2020
  • Chart Sales Value of Paclitaxel Liposome Injection in China by Regions, 2016-2020
  • Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) in China by Regions, 2016-2020
  • Chart Sales Value of Paclitaxel Injection in China by Regions, 2016-2020
  • Chart Sales Volume of Paclitaxel Liposome Injection in China, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection (Nanoparticle Albumin-bound) in China, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection in China, 2016-2020
  • Chart Sales Volume of Paclitaxel Liposome Injection in China by Regions, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection (Nanoparticle Albumin-bound) in China by Regions, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Paclitaxel Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Paclitaxel Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Injection Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of LIPOSOME in China, 2016-2020
  • Chart Sales Value and Volume of Keaili in China, 2016-2020
  • Chart Sales Value and Volume of Aiyue in China, 2016-2020
  • Chart Sales Value and Volume of ANZATAX in China, 2016-2020
  • Chart Sales Value and Volume of TAXOL in China, 2016-2020        
  • Chart Referential Prices of LIPOSOME in China by Regions, 2020-2021        
  • Chart Referential Prices of Keaili in China by Regions, 2020-2021
  • Chart Referential Prices of Aiyue in China by Regions, 2020-2021     
  • Chart Referential Prices of ANZATAX in China by Regions, 2020-2021          
  • Chart Referential Prices of TAXOL in China by Regions, 2020-2021
  • Chart Forecast on Sales Value of Liposome Injection in China, 2021-2025
  • Chart Forecast on Sales Value of Injection (Nanoparticle Albumin-bound) in China, 2021-2025
  • Chart Forecast on Sales Value of Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Liposome Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Injection (Nanoparticle Albumin-bound) in China, 2021-2025
  • Chart Forecast on Sales Volume of Injection in China, 2021-2025